Unveiling the Link: Mast Cell Activation Syndrome & Neurodiversity

Key Takeaways:

Takeaway	Details
Mast Cells and Their Roles	Found throughout the body including the brain; role in allergies, influence inflammation, stress responses, communication with the nervous system
Brain Effects of Mast Cell Activation	Can trigger neuroinflammation without visible allergy symptoms by releasing selective inflammatory signals
Chronic Inflammation and Neurodevelopment	In Mast Cell Activation Syndrome (MCAS), ongoing mast cell activity may lead to persistent neuroinflammation that could affect brain development and function
Microglia Interaction	Mast cells engage with microglia, activating feedback loops that may alter synaptic pruning, neural connections, neurotransmitter signaling
Impact on Blood–Brain Barrier	Mast cell mediators can compromise the blood–brain barrier, allowing more inflammation in the brain
Inflammatory Markers in Autism	Some autistic individuals show increased inflammatory molecules, which sometimes align with symptom severity and repetitive behaviors
ADHD and Neuroinflammation	Research suggests possible links between ADHD, neuroinflammation, histamine signaling, and immune issues
Histamine’s Role	Histamine acts as both an immune signal and neurotransmitter; abnormal breakdown may affect attention and impulse control
Immune Function and Neurodiversity	Autism and ADHD involve complex causes; immune function may impact traits but does not define neurodivergence
Affirming Medical Care	Medical care should address immune or inflammatory issues without pathologizing neurodivergent traits
Research Limitations	Current evidence is largely preliminary; bigger studies are necessary to understand causality and treatment
Personalized Approaches	Identifying immune-related subgroups among neurodivergent people could inform targeted treatments while honoring individual differences

Introduction

Mast Cell Activation Syndrome (MCAS) is an immune disorder causing abnormal mast cell mediator release and symptoms in various organs. Neurodiversity refers to differences in neurological development, such as autism, ADHD, and dyslexia, affecting learning and sensory processing. Recent research indicates that mast cell–mediated neuroinflammation may link immune dysfunction to neurodevelopmental variation. MCAS affects up to 17% of people but is often misdiagnosed, with symptoms ranging from skin to psychiatric issues. Neurodevelopmental conditions, including ASD and ADHD, are rising globally. These trends highlight the need for frameworks that respect neurodiversity and examine potential immune-brain connections, while distinguishing hypotheses from facts and noting research gaps.

Understanding Mast Cell Activation Syndrome

Mast Cell Function and Disease

Mast cells are immune cells produced in the bone marrow and found near blood vessels throughout the body, including the brain. Known for their role in allergies, they also contribute to both innate and adaptive immunity. Human mast cells come in two main types: those releasing tryptase alone and those releasing both tryptase and chymase. When activated, mast cells quickly release pre-stored chemicals like histamine and TNF‑α, while others such as cytokines are made and released gradually. Mast cells can influence various processes, including neuroinflammation, without always causing allergic reactions. They respond to a range of triggers, infectious agents, toxins, medications, foods, nervous system signals, and stress acting as environmental and stress sensors by translating internal and external cues into immune signals.

Diagnostic Challenges and Criteria

Diagnosing Mast Cell Activation Syndrome (MCAS) is complex and debated, with two main diagnostic standards: the stricter "Consensus-1" and the broader "Consensus-2." Consensus-1 requires severe, recurrent symptoms in at least two organ systems, elevated mast cell mediators, and treatment response. Consensus-2 only needs symptoms in two systems plus one of positive mediator test, biopsy evidence, or response to therapy. The diagnostic criteria greatly affect how many people are identified; the broader standard suggests MCAS may impact up to 17% of the population. A 2024 update notes that restrictive criteria risk underdiagnosis, as many patients benefit from correct identification and treatment. Many individuals face long periods without a definitive diagnosis and may even be misdiagnosed with psychiatric disorders.

The Spectrum of Neurodiversity

Neurodiversity as a Framework

Neurodiversity refers to a wide range of neurological conditions that represent inherent variations within human brain function. Included within this spectrum are autism spectrum disorder (ASD), attention-deficit/hyperactivity disorder (ADHD), dyslexia, dyspraxia, Tourette syndrome, and additional related conditions. These diagnoses impact communication, attention, sensory processing, and social interaction through diverse mechanisms. A neurodiversity-affirming approach recognizes these differences as distinct neurological profiles rather than pathological deficits, emphasizing unique strengths and challenges associated with each. This perspective calls for acceptance, individualized support, and clinical intervention when co-occurring conditions like immune, gastrointestinal, or autonomic dysfunction cause significant distress.

Sensory Processing and Neurological Variation

More than 90% of individuals on the autism spectrum experience sensory features that include hypersensitivity (over-responsivity), hyposensitivity (under-responsivity), and sensory seeking behaviors across various sensory modalities. Neuroimaging studies have shown that sensory over-responsivity in ASD is linked to increased activation of the amygdala and a failure to habituate to sensory stimuli. While these sensory characteristics are integral to the neurodivergent experience, they may be further intensified or influenced by concurrent inflammatory states. This possibility becomes particularly relevant in the context of neuroinflammation mediated by mast cells.

ADHD and Neurobiological Variation

ADHD is defined by symptoms of inattention, motor hyperactivity, and impulsiveness, and is associated with structural and functional abnormalities in both cortical and subcortical regions. These abnormalities include reduced volume in the nucleus accumbens, amygdala, caudate, hippocampus, and putamen. The underlying causes of ADHD involve disruptions in dopaminergic, noradrenergic, and serotonergic neurotransmission, as well as genetic and environmental factors. Recent epidemiological evidence points to high comorbidity between ADHD and allergic or autoimmune diseases. Many individuals with ADHD exhibit a heightened inflammatory status, suggesting a possible link between neurobiological variation and immune system activity.

The Intersection of MCAS and Neurodiversity

Mast Cell Mediators and Neuroinflammation

Mast cell activation syndrome (MCAS) may affect brain development by promoting persistent inflammation in the nervous system. Mast cells, present near the brain and its protective membranes, can influence the blood-brain barrier and release substances that activate microglia. This activation creates a cycle of inflammation, potentially disrupting brain processes like synaptic pruning and neuronal communication. Studies have found higher levels of inflammatory molecules such as IL‑1β, TNF‑α, CXCL8, and IL‑6 in some individuals with autism; elevated TNF‑α and IL‑6 are linked to more severe symptoms and repetitive behaviors, respectively. While evidence for similar mechanisms in ADHD is less clear, research suggests possible immune involvement due to overlapping pathways with autism. Overall, immune-driven inflammation may contribute to neurodevelopmental differences in some people but does not explain all aspects of neurodiversity.

Blood–Brain Barrier Disruption

When mast cells are overactive, they release inflammatory substances like histamine, enzymes, and growth factors that can weaken the blood–brain barrier. This occurs as these signals increase enzymes and inflammation-promoting molecules, while reducing proteins that keep the barrier sealed, making it more permeable. A compromised barrier allows immune cells and inflammatory agents to enter the brain, intensifying nervous system inflammation. Additionally, mast cells release stress-related molecules such as CRH and neurotensin, which further disrupt the barrier and amplify immune activation. This breakdown of the blood–brain barrier by mast cells is suggested as one possible factor in autism spectrum disorder for some individuals, sometimes described as “brain allergy” or “focal encephalitis,” indicating local immune activity's potential impact on neurological function.

The Relationship Between Mast Cells, Microglia, and Stress

Stress links mast cell activation to neurodevelopmental outcomes. Prenatal stress can increase autism risk by causing epigenetic changes in stress-regulating genes. Stress activates the HPA axis, leading to CRH release, which both stimulates mast cells and is produced by them, forming an autocrine loop. Research indicates that CRH, along with environmental factors, activates mast cells in the amygdala, triggering microglia and resulting in abnormal synaptic pruning and neural connectivity issues. These changes may lower the "fear threshold," explaining heightened fight-or-flight responses and anxiety in autism and ADHD. Children with ASD often show reduced fear of real dangers but overreact to harmless stimuli; inflammation in the amygdala might underlie this paradox.

Histamine as a Neurotransmitter in Neurodiversity

Histamine serves both as an immune signaling molecule and a neurotransmitter, impacting alertness and the sleep–wake cycle. This dual role allows histamine to affect immune responses and cognitive functions. Research by Blasco‑Fontecilla in 2023 suggests histamine may link ADHD and allergies, possibly through low diamine oxidase (DAO) activity, which can cause histamine buildup and contribute to symptoms like inattention and hyperactivity. The brain has four histamine receptors; H1 and H2 are targeted by common medications, while H3 and H4 are mainly in the brain and immune system. Glial cells respond strongly to histamine, with microglia carrying all four receptors and astrocytes carrying H1 and H2. Histamine from mast cells may influence glial activity, potentially increasing brain inflammation. Overall, histamine signaling may connect immune activity and brain function, providing insight into neuroinflammation and neurodevelopmental differences.

MCAS, POTS, hEDS & Neurodiversity

Medical recognition is growing for the triad of mast cell activation syndrome (MCAS), postural orthostatic tachycardia syndrome (POTS), and hypermobile Ehlers-Danlos syndrome (hEDS). Studies, including Weinstock et al. (2023), report frequent co-occurrence of these conditions, though prevalence varies by diagnostic criteria. Children with hypermobility spectrum disorders and hEDS are more often diagnosed with ADHD and ASD, while autistic youths and adults show higher rates of chronic health issues; EDS is especially common among autistic females. In hEDS patients, multisystem problems are widespread, and the likelihood of POTS is greatly increased. These associations suggest possible shared mechanisms, such as connective tissue dysfunction affecting mast cells and the autonomic nervous system.

Clinical Phenotypes of MCAS in Neurodiversity

Cognitive Dysfunction and "Brain Fog"

Cognitive dysfunction is recognized as one of the most disabling neuropsychiatric manifestations in individuals with mast cell activation syndrome (MCAS). According to a 2023 systematic review encompassing 24 studies on mastocytosis, cognitive impairment was observed in 27–39% of adult patients, with the primary area of difficulty being memory. Another study highlighted that cognitive complaints occur frequently in mastocytosis, even among younger individuals, and are not merely a consequence of depression. This suggests that mast cell activity may differentially impact the neural circuits involved in emotional regulation and cognitive function. The term "brain fog" is often used to describe the subjective experience of cognitive cloudiness, poor concentration, and mental fatigue. This phenomenon is commonly reported by those with MCAS and closely parallels the cognitive challenges described by many neurodivergent individuals.

Mood, Anxiety, and Psychiatric Presentations

Psychiatric symptoms are common in mastocytosis, with depression (68–75%), anxiety/stress/irritability (27–54%), and headaches (55–69%) being frequently reported. In MCAS patients, Weinstock (2023) noted high rates of depression, generalized anxiety disorder, panic disorder, and other psychiatric conditions; two patients had attempted suicide, with one case of suicidal ideation resolving after mast cell-targeted treatment. A 2021 study found depressive symptoms correlated with lower quality of life and diagnostic difficulties in MCAS, while a 2025 survey showed MCAS patients had significantly higher rates of neurological and psychiatric disorders compared to controls. Together, these studies highlight that abnormal mast cell activation can lead to neuropsychiatric symptoms often mistaken for primary psychiatric diseases.

Sensory Sensitivity and Autonomic Symptoms

Sensory hypersensitivity, including heightened responses to light, sound, smell, pain, and touch is common in both MCAS and neurodivergent conditions. MCAS patients often experience increased sensitivity to chemicals and environmental stimuli, which overlaps with sensory processing differences seen in autism, affecting over 90% of autistic individuals. Some researchers suggest mast cell inflammation may influence sensory issues in neurodivergent people, but sensory differences in autism are neurological and should not be automatically pathologized. MCAS also frequently involves autonomic dysfunction, possibly caused by mast cell mediators' effects on nerves and blood vessels; for instance, 64% of POTS patients show mast cell hyperactivity. Autonomic symptoms like presyncope, tachycardia, blood pressure shifts, and temperature regulation problems are reported in both autistic adults and those with ADHD.

Diagnosis and Treatment

Diagnostic Challenges and Overlap with Functional Diagnoses

Diagnosing mast cell activation syndrome (MCAS) in neurodivergent individuals is complex due to episodic, multisystem symptoms that are often mistaken for psychiatric or functional disorders. MCAS's recent recognition and exclusion from medical school curricula further complicate diagnosis, while lab tests can yield false negatives because of specimen handling issues and normal tryptase levels. Neuropsychiatric symptoms like brain fog, anxiety, and mood changes may be misattributed to primary neurodevelopmental conditions, leading to delays in immunological assessment. Clinicians may also dismiss somatic complaints as behavioral issues. A neurodiversity-affirming approach requires considering both neurodivergence and immune-mediated symptoms as valid and treatable.

Pharmacological Approaches

No FDA-approved protocol exists for MCAS, but clinical practice recommends a stepwise pharmacological approach.

Therapy/Agent	Details & Notes
Non-sedating H1 and H2 receptor antagonists	First-line therapy, e.g., cetirizine, loratadine, famotidine; taken twice daily
Mast cell stabilizers	Cromolyn sodium (weak inhibitor, may trigger histamine release); ketotifen (off label, dual action)
Flavonoid supplements	Quercetin, luteolin (better brain penetration), tetramethoxyluteolin (maybe more potent); luteolin-based formulations improved ASD symptoms, decreased TNF and IL-6
LDN (Low-dose naltrexone)	Increasingly included for MCAS and depression
Vitamins	Sustained-release vitamin C (1000 mg daily), vitamin D (2000–5000 IU, depending on serum levels); standard adjuncts
Severe cases	Hydroxyurea, tyrosine kinase inhibitors (e.g., masitinib), IVIG; for refractory MCAS; masitinib led to significant improvement and recovery in most mastocytosis patients
Evidence	Current support relies mainly on case series, retrospective reviews, and consensus rather than randomized trials; more controlled studies needed to assess efficacy and distinguish effects from placebo

Dietary and Environmental Interventions

A 3-week gluten-free, dairy-free, low-histamine diet is commonly recommended for MCAS management. High-histamine foods (e.g., aged cheeses, fermented foods, processed meats, alcohol) and histamine liberators can worsen symptoms. However, elimination diets may risk nutritional deficiencies, food anxiety, and social isolation, risks heightened for neurodivergent individuals with sensory-related eating restrictions. Dietary changes should include nutrition support and are not treatments for neurodivergent traits. Identifying and avoiding environmental triggers like mold/mycotoxins, chemicals, and stress are also important non-pharmacological strategies. Mycotoxin exposure, particularly ochratoxin A, has been linked to increased ASD symptoms, especially in boys.

Key Studies Comparing MCAS and Neurodiversity Research

Study	Population	Group	Main finding	Clinical implication
Theoharides, Kavalioti & Tsilioni (2019)	Review (ASD)	Autism	CRH and environment activate mast cells and microglia, affecting synaptic pruning and amygdala response.	Mast cell/microglia inhibitors (e.g., luteolin) may help certain autistic subgroups.
Song, Lu, Yuan et al. (2020)	Review (ADHD)	ADHD	Mast cell–driven neuroinflammation may underlie ADHD, via glia interaction, HPA axis, and blood–brain barrier disruption.	Suggests mast cell stabilizers as potential ADHD treatments.
Kempuraj, Thangavel et al. (2021)	Review (neuroinflammation)	Broad neuropsychiatric	Luteolin suppresses mast cell/microglia activation, NF-κB/STAT3 signaling, and cognitive deficits.	Supports luteolin for neuroprotection in inflammatory conditions.
Blasco-Fontecilla (2023)	Conceptual (ADHD/allergy)	ADHD	Highlights histamine and DAO deficiency as a link between ADHD and allergies.	DAO supplements and antihistamines may aid ADHD management.
Weinstock, Nelson & Blitshteyn (2023)	8 MCAS patients	ADHD, depression, anxiety, OCD, bipolar	All improved with mast cell therapy; most had comorbid dysautonomia.	Screen neuropsychiatric patients with systemic symptoms for MCAS.
Kovacheva, Gevezova, Maes & Sarafian (2024)	Review (ASD)	Autism	Mast cell cytokines drive neuroinflammation; ASD incidence is higher in mastocytosis.	Cytokine profiles may guide biomarker development and therapies.
Cognitive alterations systematic review (2023)	24 studies (mastocytosis)	Mixed neuropsychiatric	High rates of depression, anxiety, cognitive impairment, and headaches in mastocytosis.	Routine neuropsychiatric assessment recommended.
Weinstock et al. (2025)	553 MCAS vs 558 controls	Mixed (ADHD, anxiety, depression, PTSD)	Most neurologic/psychiatric disorders more common in MCAS.	Confirms high neuropsychiatric burden—systematic evaluation supported.
POTS–hEDS–MCAS association study (2025)	Young patients	Triad overlap	Strong link between POTS, hypermobility, and MCAS, depending on criteria.	Comprehensive triad screening advised if any one condition is present.

Broader Implications

Toward Neurodiversity-Affirming and Trauma-Informed Care

Understanding mast cell biology alongside neurodiversity has important clinical implications. Neurodiversity-affirming care supports individuals by addressing medical issues like immune dysregulation, rather than trying to change neurodivergent traits. Recognizing that inflammation can worsen sensory, executive, or emotional challenges helps clinicians offer targeted support while respecting neurological identity. Trauma-informed care is crucial, as both MCAS and neurodivergent patients often face misdiagnosis and harmful interventions. For example, the Weinstock case series shows patients improved only after proper MCAS treatment following years of ineffective psychiatric care. Clinicians should validate symptoms, use humility, and pursue thorough evaluations.

Personalized Medicine and Subgroup Identification

Identifying immune subgroups in neurodivergent populations could advance research and clinical care. For example, children with mastocytosis show ASD rates over six times higher than average, indicating a link between mast cell–driven neuroinflammation and autism. Likewise, histamine dysregulation, through DAO deficiency or mast cell overactivation, may underline some ADHD symptoms and offer a biological treatment target. Personalized assessments might include mediator profiling, cytokine panels, DAO testing, and evaluation for the MCAS–POTS–hEDS triad when systemic symptoms are present. Treatments would then be tailored to each person’s immune profile, supported by neurodiversity-affirming psychosocial care.

Limitations and Future Directions

There are key limitations to consider. Most links between mast cell activation and neurodevelopmental variation rely on indirect evidence from epidemiology, animal studies, in vitro work, or small case series; causality and treatment efficacy have not been shown in large, randomized trials. MCAS diagnostic criteria remain debated, and high prevalence estimates may reflect overcounting. Neurodiversity arises from complex factors beyond immunity, so oversimplifying causes should be avoided. Future research should include prospective mast cell mediator studies, randomized trials of mast cell–targeted therapies, investigations into DAO activity in ADHD, longitudinal prenatal mast cell studies, development of screening tools, and qualitative studies focusing on neurodivergent individuals with immune issues.

Conclusion

Mast Cell Activation Syndrome intersects with neurodiversity, revealing links between immune function and neurological differences. Mast cells can influence neurodevelopmental traits like ASD and ADHD via neuroinflammatory mechanisms. Early clinical evidence suggests mast cell-focused treatments may improve neuropsychiatric symptoms in MCAS patients, though more research is needed. A balanced, neurodiversity-affirming approach incorporates immunology as part of comprehensive care without reducing neurodivergent identity to pathology. Future advances may enable identification of mast cell–driven subgroups and personalized therapies, supporting both biological and individual diversity.

References

1. Afrin, L. B., et al. (2020). Diagnosis of mast cell activation syndrome: A global “consensus-2.” Diagnosis, 8(2), 137–152. https://doi.org/10.1515/dx-2020-0005

2. Akin, C. (2022). How to evaluate the patient with a suspected mast cell disorder. Hematology, 2022(1), 55–63. https://doi.org/10.1182/hematology.2022000366

3. Blasco-Fontecilla, H. (2023). Is histamine and not acetylcholine the missing link between ADHD and allergies? Journal of Clinical Medicine, 12(16), 5350. https://doi.org/10.3390/jcm12165350

4. Kempuraj, D., Thangavel, R., et al. (2021). Neuroprotective effects of flavone luteolin in neuroinflammation and neurotrauma. BioFactors, 47, 190–197. https://doi.org/10.1002/biof.1687

5. Kovacheva, E., Gevezova, M., Maes, M., & Sarafian, V. (2024). Mast cells in autism spectrum disorder — The enigma to be solved? International Journal of Molecular Sciences, 25(5), 2651. https://doi.org/10.3390/ijms25052651

6. Song, Y., Lu, M., Yuan, H., Chen, T., & Han, X. (2020). Mast cell–mediated neuroinflammation may have a role in attention deficit hyperactivity disorder (Review). Experimental and Therapeutic Medicine, 20(2), 714–726. https://doi.org/10.3892/etm.2020.8789

7. Theoharides, T. C., Kavalioti, M., & Tsilioni, I. (2019). Mast cells, stress, fear and autism spectrum disorder. International Journal of Molecular Sciences, 20(15), 3611. https://doi.org/10.3390/ijms20153611

8. Weiler, C. R. (2020). Mast cell activation syndrome: Tools for diagnosis and differential diagnosis. Journal of Allergy and Clinical Immunology: In Practice, 8(2), 498–506. https://doi.org/10.1016/j.jaip.2019.08.022

9. Weinstock, L. B., Nelson, R. M., & Blitshteyn, S. (2023). Neuropsychiatric manifestations of mast cell activation syndrome and response to mast-cell-directed treatment: A case series. Journal of Personalized Medicine, 13(11), 1562. https://doi.org/10.3390/jpm13111562

10. Weinstock, L. B., et al. (2025). Prevalence and treatment response of neuropsychiatric disorders in mast cell activation syndrome. Brain, Behavior, & Immunity – Health. https://doi.org/10.1016/j.bbih.2025.100906